What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?
Written by Robert Izquierdo for The Motley Fool -> Chief People Officer Francis Lo disposed of 39,741 Common Stock shares on June 4, 2026, for a total transaction value of ~$695,000 based on a weighted average price of $17.49 per share. The transaction represented 13.56% of Lo'
Chief People Officer Francis Lo disposed of 39,741 Common Stock shares on June 4, 2026, for a total transaction value of ~$695,000 based on a weighted average price of $17.49 per share.
The transaction represented 13.56% of Lo's direct holdings at the time of execution, reducing direct ownership to 250,934 shares.
All shares sold were held directly; the filing reflects a derivative context involving the exercise of 19,521 options prior to sale, with no indirect entity involvement.
Francis Lo, Chief People Officer of Adaptive Biotechnologies (NASDAQ:ADPT) , reported the sale of 39,741 shares of Common Stock for a transaction value of approximately $695,000, as disclosed in a SEC Form 4 filing .
Transaction and post-transaction values based on SEC Form 4 weighted average reported price ($17.49).
Adaptive Biotechnologies leverages a proprietary immune medicine platform to deliver advanced diagnostic and monitoring solutions for cancer, autoimmune disorders, and infectious diseases. Its strategic partnerships enhance its capabilities in both therapeutic development and next-generation diagnostics.
The company’s integrated approach positions it at the forefront of immune-driven precision medicine, supporting both clinical and research applications at scale.
Looking at the sale of Adaptive Biotechnologies stock by Chief People Officer Francis Lo shows it involved the exercise and sale of stock options. This is a routine action adopted by many insiders across companies. So Lo’s June 4 disposition is not out of the ordinary.
